Systemic retinoid (nodular/severe acne)
Isotretinoin is an oral retinoid reserved for severe nodular acne that has not responded to other treatments. It works by reducing sebum production and sebaceous gland size, drying the skin from within. It is a medicine with significant adverse effects — above all severe teratogenicity — so it requires close medical supervision and, in women of childbearing potential, a mandatory pregnancy prevention programme.
Also known as: Isotretinoína, Roacutan
The combination of Isotretinoin with tetracyclines (Doxycycline) should be avoided: both may cause pseudotumor cerebri (benign intracranial hypertension).
Both isotretinoin and tetracyclines (doxycycline) are associated with cases of pseudotumor cerebri, a benign intracranial hypertension with a risk of visual damage. The isotretinoin label documents cases with concomitant tetracycline use and recommends avoiding the combined treatment. The mechanism is additive, with no defined safe dose. If the combination is unavoidable, monitor early signs — persistent headache, nausea, vomiting and visual disturbances — and refer urgently if papilledema appears. In severe acne, consider therapeutic alternatives that do not combine the two classes.
Isotretinoin + doxycycline: avoid the combination — risk of pseudotumor cerebri (benign intracranial hypertension) by additive effect.
Both isotretinoin and tetracyclines are associated with cases of pseudotumor cerebri; concomitant use increases the risk additively.
Monitor for headache, nausea, vomiting, visual disturbances and papilledema.
Persistent headache, visual disturbances, papilledema.
Avoid the combination. If unavoidable, monitor for early signs of pseudotumor cerebri.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d ; approved Doxycycline label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0fbf63a-e75c-40cf-b2e9-429deaac899d
Administration of Isotretinoin should be avoided during and shortly after Minocycline therapy: each drug alone has been associated with pseudotumor cerebri.
The minocycline label is explicit: isotretinoin administration should be avoided shortly before, during and shortly after minocycline therapy, because each drug alone is associated with pseudotumor cerebri. The risk is an additive effect on intracranial pressure, with the potential for permanent visual damage if unrecognized. In patients who need both therapies at different times in the course of acne, a non-overlapping interval should be ensured and headache, vomiting and visual disturbances monitored, with urgent referral for any suspicion of papilledema.
Isotretinoin + minocycline: avoid administration during and shortly after minocycline — risk of pseudotumor cerebri.
Both isotretinoin and minocycline may cause pseudotumor cerebri; concomitant or closely sequential use increases the risk.
Monitor for headache, nausea, vomiting and visual disturbances.
Persistent headache, visual disturbances or papilledema.
Avoid isotretinoin administration during and shortly after minocycline.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d ; approved Minocycline label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06
Isotretinoin + Phenytoin: caution due to the possible additive effect on bone loss (phenytoin-associated osteomalacia).
Phenytoin is known to cause osteomalacia and isotretinoin may also affect bone metabolism, especially in growing adolescents. The isotretinoin label found no change in phenytoin pharmacokinetics, but no formal studies assessed the interactive effect on bone loss and caution is recommended. The risk is higher in prolonged treatment, osteoporosis, anorexia nervosa or chronic therapy affecting vitamin D. Consider bone health monitoring and reassess the need for each drug during long-term treatment.
Isotretinoin + phenytoin: caution — possible additive effect on bone loss (phenytoin osteomalacia).
Phenytoin is known to cause osteomalacia; no formal studies assessed the interactive effect on bone loss with isotretinoin, but the label advises caution.
Monitor for signs of bone loss or fractures during prolonged therapy.
Bone pain, fractures or osteomalacia during prolonged treatment.
Use with caution; consider bone health monitoring during prolonged treatment.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d ; approved Phenytoin label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3580e6a8-f7c3-44a0-a1eb-2a84ae589d21
Isotretinoin + systemic corticosteroids (Prednisolone): caution due to the possible additive effect on bone loss.
Systemic corticosteroids, such as prednisolone, may induce osteoporosis and osteomalacia, especially in prolonged therapy. The isotretinoin label warns that drugs causing drug-induced osteoporosis/osteomalacia, including systemic corticosteroids, place the patient at increased risk of bone loss and fractures when used together. The risk is particularly relevant in adolescents and in patients practising impact sports. Use the lowest corticosteroid dose and shortest duration possible, consider calcium/vitamin D supplementation as appropriate and monitor musculoskeletal symptoms.
Isotretinoin + prednisolone: caution — systemic corticosteroids may increase bone loss with isotretinoin.
Systemic corticosteroids may cause drug-induced osteoporosis/osteomalacia; the isotretinoin label warns of the increased risk of bone loss with concomitant use.
Monitor for signs of bone loss during prolonged therapy.
Bone pain, fractures or osteoporosis during prolonged treatment.
Use with caution; consider bone density monitoring during prolonged treatment.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d ; approved Prednisolone label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=757b41c4-a0fe-4a09-8816-a4cdb7558f41
Oral isotretinoin absorption is enhanced by high-fat meals (high lipophilicity) — "oral absorption of isotretinoin is enhanced when given with a high-fat meal".
Take with a high-fat meal to maximise absorption.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Alcohol increases the risk of hypertriglyceridaemia and hepatic changes during isotretinoin treatment, and may worsen dryness and central nervous system effects.
Avoid or strongly limit alcohol intake during treatment.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Risk of bone loss with prolonged or repeated isotretinoin use — labels document that concomitant drugs affecting bone metabolism (phenytoin, corticosteroids) "may weaken your bones".
Consider bone mineral density monitoring in prolonged or repeated treatment and in at-risk patients.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Isotretinoin raises triglycerides and cholesterol; patients with pre-existing dyslipidaemia have an increased risk of pancreatitis.
Monitor fasting lipid profile before and during treatment; if triglycerides are raised, consider dose reduction or discontinuation.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Risk of depression, suicidal ideation, aggression and mood changes associated with isotretinoin — monitor all patients, especially those with psychiatric history.
Inform the patient and family to watch for mood changes; discontinue and evaluate if depressive symptoms appear.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Risk of transaminase elevation and hepatotoxicity during isotretinoin treatment; pre-existing hepatic disease increases the risk.
Monitor transaminases before and during treatment (baseline and periodic); use with caution in hepatic disease.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Severe, well-documented teratogenicity — "There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking isotretinoin capsules in any amount, even for short periods of time" (label).
Contraindicated in pregnancy and in women who may become pregnant without reliable contraception; require a negative pregnancy test and effective contraception 1 month before, during and 1 month after.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Severe teratogenicity — "extremely high risk that severe birth defects will result if pregnancy occurs while taking isotretinoin capsules in any amount, even for short periods of time"; any exposed fetus may be affected.
Contraindicated in any trimester; never use during pregnancy.
Unknown whether it is excreted in breast milk; the safety profile does not allow breastfeeding during treatment.
Reliable contraception (ideally dual) mandatory 1 month before, during and 1 month after treatment; negative pregnancy test before starting.
DailyMed/FDA (NIH/NLM) — approved Isotretinoin label (Sotret): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a26c5e-9c3e-4781-8c08-62b91d21a68d
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Retinoid that reduces sebaceous gland activity (size and sebum production), normalises follicular keratinisation and has anti-inflammatory effect; it is the only drug that modifies the underlying disease in severe nodular acne.
Acts through binding to retinoic acid nuclear receptors (RAR), modulating gene expression in keratinocytes and sebocytes: reduces sebocyte proliferation and differentiation, sebum production and follicular hyperkeratosis, and inhibits neutrophil chemotaxis.
Oral absorption is enhanced with high-fat meals (high lipophilicity — "oral absorption of isotretinoin is enhanced when given with a high-fat meal"); bioavailability is about 25% fasting, increasing when taken after a meal.
Metabolised in the liver (CYP450 isoenzymes — "metabolism are 2C8, 2C9, 3A4, and 2B6") to active metabolites (4-oxo-isotretinoin); elimination is hepatic and renal, without relevant accumulation on repeated dosing.
Elimination half-life of about 21 hours ("elimination half-lives (t 1/2 ) of isotretinoin and 4-oxo-isotretinoin were 21... hours"); the 4-oxo metabolite has a half-life of about 90 hours.
